AMEX Biotechnology Stock
Hot Biotechnology Stock
NASDAQ Biotechnology Stock
NYSE Biotechnology Stock
OTCBB Biotechnology Stock
Penny Biotechnology Stock

Biotechnology Stock

Salix Pharmaceuticals Ltd

Our website address is www.salix.com . We make available free of charge through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission. more

Neopharm, Inc

You should carefully consider the following risk factors, in addition to the other information set forth in this document as well as other information filed in periodic reports we file with the SEC. Each of these risk factors could adversely affect our business, operating results and financial condition, as well as the value of an investment in our common stock. more

Laureate Edu

This Annual Report on Form 10-K and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in statements made, or to be made, by the Company’s senior management contain, or will contain, “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or ... more

Pain Therapeutics, Inc

We are a biopharmaceutical company that develops novel drugs for pain management and oncology. We have three investigational drug candidates in clinical programs. Remoxy and PTI-202 are proprietary, abuse-resistant forms of opioid drugs. Oxytrex is a novel, next-generation painkiller that potentially offers less physical dependence than currently marketed opioid painkillers. We are also ... more

Pall Corporation

Pall Corporation, a New York corporation incorporated in July 1946, and its subsidiaries (hereinafter collectively called the “Company” or referred to as “we” or “our” unless the context requires otherwise) is a leading supplier of integrated filtration, separation and purification technologies, principally made by the Company using its engineering capability, ... more

Biomarin Pharma, Inc

,” and other sections of this Form 10-K. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in “ Risk Factors ,” as well as those discussed elsewhere in this Form 10-K. You should carefully consider that information before you make an investment decision. more

Adams Respiratory

      We are a specialty pharmaceutical company focused on late-stage development, commercialization and marketing of over-the -counter, or OTC, and prescription pharmaceuticals for the treatment of respiratory disorders. We currently market three OTC products under our Mucinex brand, one product under our Humibid brand, two products under our Delsym brand, and four ... more

Mentor Corporation

") to Coloplast for total consideration of $463,225,000, of which $456,137,500 would be in cash and $7,087,500 in non-cash consideration, and on June 2, 2006 we completed this sale to Coloplast.  more

Peregrine Pharmaceuticals, Inc

Conduct and Ethics. The Board of Directors (the "Board") of the Company adopted the corporate governance policies and charters. Copies of the following corporate governance documents are posted on our website, and are available free of charge, at www.peregrineinc.com : (1) Peregrine Pharmaceuticals, Inc. Code of Business Conduct and Ethics ... more

Blockbuster, Inc.

Opportunity Ventures” and state laws and regulations that govern the offer and sale of franchises and franchise relationships. If we want to offer and sell a franchise, we are required to furnish to each prospective franchisee a current franchise offering circular prior to the offer or sale of a franchise. In addition, a number of states require us to comply with registration or filing ... more

Genelabs Technology

Genelabs Technologies, Inc., referred to as Genelabs or the Company, is a biopharmaceutical company engaged in the discovery and development of pharmaceutical products to improve human health. Our business objective is to develop a competitive advantage by focusing on drug targets for which we can rapidly optimize lead compounds, with the goal of developing drugs with ... more

Regeneron Pharmaceuticals Cp

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron Pharmaceuticals, Inc., and actual events or results may differ materially. These statements concern, among other things, the possible success and therapeutic applications of ... more

Geovax Labs, Inc

- Previous Operations"). Included in those operations was Suncoast Automation, Inc., which the Company sold on April 28, 2003. We were unsuccessful in generating income from or positive cash flow from any of our operations, including Suncoast's operations. Our operations in Greece and Suncoast operations have been included and presented as "Discontinued Operations" in this ... more

Momenta Pharmaceuticals, Inc

We have incurred significant losses since our inception in May 2001. At December 31, 2006, our accumulated deficit was approximately $125.5 million. We have not generated revenues from the sale of any products to date. We expect that our annual operating losses will increase over the next several years as we expand our drug commercialization, development and discovery efforts. To ... more

United Therapeutics

The company develops therapeutic products for patient with chronic and life-threatening cardiovascular, cancer, and infectious diseases. It also offers telemedicine services for detection of cardiac arrhythmias and ischemic heart disease. more